SEC 13F Intelligence

Octagon Capital Advisors LP / ANTX

Octagon Capital Advisors LP’s An2 Therapeutics Inc Position

Does Octagon Capital Advisors LP own An2 Therapeutics Inc (ANTX)? Not currently — the last reported position was 3.22M shares worth $7M in Q2 2024; the fund’s latest 13F (Q1 2026) no longer reports it.

Position Value
$7M
Q2 2024
Shares
3.22M
% of Portfolio
+1.09%
Quarters Held
5
position exited

Position History ANTX

Reported value by quarter
Q2 ’23: $6MQ2 ’23Q3 ’23: $14MQ3 ’23Q4 ’23: $14MQ4 ’23Q1 ’24: $4MQ1 ’24Q2 ’24: $7MQ2 ’24filingsflow.com
QuarterSharesValue% of Portfolio
Q2 20243.22M$7M+1.09%
Q1 20241.10M$4M+0.43%
Q4 2023664.6K$14M+2.18%
Q3 2023867.6K$14M+2.14%
Q2 2023720.9K$6M+0.85%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Octagon Capital Advisors LP’s full portfolio or all institutional holders of ANTX.